Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year High - Here's Why

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report)'s stock price reached a new 52-week high on Tuesday . The company traded as high as $40.03 and last traded at $40.02, with a volume of 251580 shares changing hands. The stock had previously closed at $37.36.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several recent analyst reports. Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals in a research note on Monday, January 6th. They set an "overweight" rating and a $57.00 price objective for the company. Cowen reiterated a "buy" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, Piper Sandler restated a "neutral" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Stock Performance

The stock's 50 day simple moving average is $37.36 and its 200-day simple moving average is $34.81. The firm has a market cap of $2.12 billion, a price-to-earnings ratio of 35.89 and a beta of 0.90.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now owns 10,149 shares of the company's stock, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 9.30% of the stock is owned by insiders.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in SUPN. GAMMA Investing LLC boosted its holdings in Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock valued at $25,000 after purchasing an additional 398 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after purchasing an additional 870 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Supernus Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock worth $61,000 after acquiring an additional 352 shares during the period. Newbridge Financial Services Group Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at $72,000. Finally, Venturi Wealth Management LLC acquired a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at about $92,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.